The majority of inflammatory rheumatic diseases (IRDs) affect females more frequently and many have peaks in their childbearing age…

MERGING artificial intelligence with targeted electrical brain stimulation has been found to improve certain human brain functions…

PIONEERING researchers have used human data to assess the speed at which different processes lead to the development of Alzheimer’s disease…

An insightful study conducted in the USA shared the problematic link between fast-food restaurants and Type 2 diabetes (T2D)…

Further analysis demonstrated that dapagliflozin increased the likelihood of regression in patients with a UACR of 300 or more in 3,860 patients…

Although approximately 60% of patients with diffuse large B-cell lymphoma (DLBCL) can be cured, the remaining 40% have relapsed or refractory disease (R/R DLBCL). Substantial unmet need remains for effective, safe therapies for these patients. Novel targeted approaches to the treatment of R/R DLBCL include CD19-directed antibodies, antibody–drug conjugates, bispecific monoclonal antibodies, and anti-CD-19 chimeric antigen receptor (CAR) T-cell therapies.

A number of misconceptions prevail in nail melanoma. This short essay tries to clarify some of these issues.

Interviewing Peter Lio, Clinical Assistant Professor of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine